Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis

References

• Rumgay H, Arnold M, Ferlay J., et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int, J, Cancer. 2018;142(12):2471–2477. doi:10.1002/ijc.31280
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818–824. doi:10.1289/ehp.0901388
   PubMed Web of Science ®Google Scholar
• Mittal S. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2016;14:124–131.e1.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol. 2019;71(3):523–533. doi:10.1016/j.jhep.2019.05.008
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72(2):262–276. doi:10.1016/j.jhep.2019.11.017
   PubMed Web of Science ®Google Scholar
• Kim J, Kang W, Sinn DH, et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol. 2020;26(4):516–528. doi:10.3350/cmh.2020.0016
   PubMed Web of Science ®Google Scholar
• Zhang X-P. Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study. Int J Surg Lond Engl. 2023;109(4):679–688. doi:10.1097/JS9.0000000000000204
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi:10.1245/s10434-019-07227-9
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria. Ann Surg Oncol. 2020;27:2321–2331.
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee J-H, Lim Y-S, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383–1391.e6. doi:10.1053/j.gastro.2015.02.055
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44(4):891–895. doi:10.1002/hep.21341
   PubMed Web of Science ®Google Scholar
• Chen K, Xia Y, Wang H, et al. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One. 2013;8(2):e57397. doi:10.1371/journal.pone.0057397
   PubMed Web of Science ®Google Scholar
• Wei W, Jian P-E, Li S-H, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 2018;38(1):61. doi:10.1186/s40880-018-0331-y
   PubMed Web of Science ®Google Scholar
• Wang Z. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24:2074–2081.
   PubMed Web of Science ®Google Scholar
• Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol off J Am Soc Clin Oncol. 2013;31(28):3501–3508. doi:10.1200/JCO.2012.44.5643
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer Oxf Engl. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi:10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• Li S-H, Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy With FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, Phase III, randomized study. J Clin Oncol. 2023;41(10):1898–1908. doi:10.1200/JCO.22.01142
   PubMed Web of Science ®Google Scholar
• Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: a Systematic Review and Network Meta-Analysis - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/34540675/. Accessed March 24, 2024.
   Google Scholar
• Shi M, Guo R-P, Lin X-J, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245(1):36–43. doi:10.1097/01.sla.0000231758.07868.71
   PubMed Web of Science ®Google Scholar
• Shi M. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol. 2010;16(2):264–269. doi:10.3748/wjg.v16.i2.264
   PubMed Web of Science ®Google Scholar
• Elsayes KM. 2017 Version of LI-RADS for CT and MR Imaging: an Update. Radiogr Rev Publ Radiol Soc N Am Inc. 2017;37:1994–2017.
   Google Scholar
• Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242(2):252–259. doi:10.1097/01.sla.0000171307.37401.db
   PubMed Web of Science ®Google Scholar
• Zhang H, Yuan S-X, Dai S-Y, et al. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg. 2014;38(4):947–957. doi:10.1007/s00268-013-2365-2
   PubMed Web of Science ®Google Scholar
• Chang YJ, Chung KP, Chang YJ, Chen LJ. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg. 2016;103(11):1513–1520. doi:10.1002/bjs.10196
   PubMed Web of Science ®Google Scholar
• He M-K, Zou R-H, Wei W, et al. Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: results of a single-center double-blind prospective randomized controlled trial. J Vasc Interv Radiol JVIR. 2018;29(8):1068–1077.e2. doi:10.1016/j.jvir.2018.03.027
   PubMed Web of Science ®Google Scholar
• Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843–3849. doi:10.3748/wjg.v21.i13.3843
   PubMed Web of Science ®Google Scholar
• Qu K, Yan Z, Wu Y, et al. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30(5):925–932. doi:10.1111/jgh.12873
   PubMed Web of Science ®Google Scholar
• Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 2008;68(20):8635–8642. doi:10.1158/0008-5472.CAN-08-0917
   PubMed Web of Science ®Google Scholar
• Fang Z-T. Transcatheter arterial embolization promotes liver tumor metastasis by increasing the population of circulating tumor cells. Oncol Targets Ther. 2013;6:1563–1572.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang J, Wang Y, et al. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Medicine. 2022;101(51):e32390. doi:10.1097/MD.0000000000032390
   PubMed Web of Science ®Google Scholar
• Si T, Huang Z, Khorsandi SE, Ma Y, Heaton N. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review with meta-analysis. Front Bioeng Biotechnol. 2022;10:1010824. doi:10.3389/fbioe.2022.1010824
   PubMed Web of Science ®Google Scholar
• Poon RT-P, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg. 2002;194(5):592–602. doi:10.1016/S1072-7515(02)01163-8
   PubMed Web of Science ®Google Scholar
• Xu X-F, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma. JAMA Surg. 2019;154(3):209–217. doi:10.1001/jamasurg.2018.4334
   PubMed Web of Science ®Google Scholar
• Qiu Z-C, Li C, Zhang Y, et al. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection. Langenbecks Arch Surg. 2023;408(1):250. doi:10.1007/s00423-023-02993-3
   PubMed Web of Science ®Google Scholar
• Solitary Large Hepatocellular Carcinoma: staging and Treatment Strategy | PLOS ONE. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155588. Accessed March 24, 2024.
   Google Scholar
• Fang Q, Xie Q-S, Chen J-M, et al. Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: a single-center experience in China. Hepatobiliary Pancreat Dis Int. 2019;18(6):532–537. doi:10.1016/j.hbpd.2019.09.001
   PubMed Web of Science ®Google Scholar
• Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection - Wakayama Journal of Surgical Oncology; 2017. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jso.24501. Accessed March 24, 2024.
   Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected] & European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H-C, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–260. doi:10.1159/000488035
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Association K, National Cancer Center N; Korean Liver Cancer Association & National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13(3):227–299. doi:10.5009/gnl19024
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3–4):458–468. doi:10.1159/000343875
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Wei Z, et al. Exploratory study of microparticle transcatheter arterial chemoembolization combined with resection for huge hepatocellular carcinoma. iLIVER. 2022;1(1):35–42. doi:10.1016/j.iliver.2022.01.001
   Google Scholar
• Ryu T, Takami Y, Wada Y, et al. A clinical scoring system for predicting microvascular invasion in patients with hepatocellular carcinoma within the milan criteria. J Gastrointest Surg off J Soc Surg Aliment Tract. 2019;23(4):779–787. doi:10.1007/s11605-019-04134-y
   Google Scholar
• Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transplant off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2009;15:574–580.
   Google Scholar
• Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174–8185. doi:10.1245/s10434-021-09901-3
   PubMed Web of Science ®Google Scholar
• Regimbeau JM. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol. 2004;85(1):36–41. doi:10.1002/jso.10284
   PubMed Web of Science ®Google Scholar
• Kawabe N. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open Open Access J Gastro Hepatol. 2021;5:705–711.
   Google Scholar
• Yang F, Ma L, Yang Y, et al. Contribution of hepatitis B virus infection to the aggressiveness of primary liver cancer: a clinical epidemiological study in Eastern China. Front Oncol. 2019;9:370. doi:10.3389/fonc.2019.00370
   PubMed Web of Science ®Google Scholar
• Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721. doi:10.1001/jamasurg.2018.2721
   PubMed Web of Science ®Google Scholar